Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Imsidolimab · ANB-019

Monoclonal antibody · Antagonist of Interleukin-36 receptor (IL36R) · developed by Vanda Pharmaceuticals

Phase 3 Most advanced trial (none active)
VNDA Developer
4 Registered trials

What is Imsidolimab?

Imsidolimab is a humanized monoclonal antibody that binds the interleukin-36 receptor (IL-36R) and blocks signaling by the pro-inflammatory cytokine IL-36. It is being studied in ulcerative colitis, acne vulgaris and generalized pustular psoriasis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ANB-019
Drug type
Monoclonal antibody
Targets
Interleukin-36 receptor (IL36R)
Mechanism
Antagonist of Interleukin-36 receptor (IL36R)
Pathways
IL-36/IL-36R signaling
Therapy area
Dermatology
Developer
Vanda Pharmaceuticals (VNDA)
Also in trials of
CNTB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
KX89J0DFZ8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05366855 Phase 3 Generalized Pustular Psoriasis Terminated VNDA
NCT05352893 Phase 3 Generalized Pustular Psoriasis Completed VNDA
NCT04856917 Phase 2 Acne Vulgaris Completed VNDA
NCT04700449 Phase 2 Moderate to Severe Ulcerative Colitis Completed CNTB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne VulgarisGeneralized Pustular PsoriasisModerate to Severe Ulcerative Colitis

More from Vanda Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the VNDA page.

Follow VNDA, the company behind Imsidolimab

See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VNDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.